Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurobiological Technologies amends follow-on

NTII amended its proposed follow-on and now hopes to sell

Read the full 100 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE